DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SAN ANTONIO, March 01, 2018 -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has been approved for membership in the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI). EDRN brings government, academic and industry leaders together to accelerate the discovery, development and validation of biomarkers for cancer risk and early detection.
“Collaboration with the National Cancer Institute’s Early Detection Research Network is an important step in the development of CyPath© Lung, our non-invasive, early-stage lung cancer test. EDRN also offers valuable resources to advance our promising oncological diagnostics for prostate and bladder cancers,” said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies. “EDRN and its members share many of our objectives, including expanding our knowledge of the biology of cancer, developing and testing promising technologies for the early detection of cancer, and promoting collaboration to advance the clinical application of tests like CyPath© Lung.”
bioAffinity Technologies’ Executive Vice President Vivienne Rebel, PhD, MD, and Director of Operations Xavier Reveles, MS GC(ASCP)cm, will attend next week’s 10th EDRN Scientific Workshop from March 6-8, 2018, in Bethesda, MD. The workshop will focus on standards and regulatory science, novel technologies for precision detection, imaging, clinical and validation science, alliances and consortia on biomarkers, and non-profit foundations’ support for biomarkers.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company that develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas San Antonio. The Company’s initial product is CyPath® Lung, a diagnostic assay for the detection of early-stage lung cancer.
Contact: Maria Zannes, 505.400.9747
